The management of urothelial cancer is rapidly evolving and the multidisciplinary approach is gaining ground. For example in muscle-invasive bladder cancer (MIBC), bladder preservation with multimodality treatment including chemotherapy and irradiation has become a real alternative to cystectomy.  In clinical trials, immunotherapy is evaluated earlier in the disease spectrum, even in the NMIBC setting.

A patient seen by a multidisciplinary team is more likely to receive a balanced perspective on the risks and benefits of all available treatment options. A physician who wants to contribute successfully to a multidisciplinary team should be familiar with the entire spectrum of management strategies.

Next, to the treating physicians, supportive physicians such as pathologists and radiologists and allied healthcare professionals such as nurse specialists and pharmacists have an important role in the multidisciplinary team.

BLADDR focusses on this multidisciplinarity.

It’s key to us that the faculty and the participants form a fusion of disciplines who can learn from each other.